Ganga Pharmaceuticals Ltd Stock Price Today (NSE: GANGAPHARM)
Fundamental Score
Ganga Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Ganga Pharmaceuticals Ltd share price today is ₹12.00, up +0.00% on NSE/BSE as of 13 February 2026. Ganga Pharmaceuticals Ltd (GANGAPHARM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹6.90 (Cr). The 52-week high for GANGAPHARM share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 86.25x, GANGAPHARM is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 1.13% and a debt-to-equity ratio of 0.19.
Ganga Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Ganga Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Ganga Pharmaceuticals Share Price: A Financial Stability Analysis
The Indian pharmaceutical industry, known for its generic drug manufacturing prowess, is currently facing increased regulatory scrutiny and pricing pressures, impacting profitability. This analysis focuses on the financial stability of Ganga Pharmaceuticals Ltd, evaluating factors influencing its share price. Currently, the Ganga Pharmaceuticals share price stands at ₹12.0, with a Price-to-Earnings (PE) ratio of 86.25 and a Return on Capital Employed (ROCE) of 3.18%. This assessment forms part of an 80-parameter fundamental audit, verified by Sweta Mishra, aimed at providing a comprehensive overview of the company's financial health.
A key metric to examine is the company's PE ratio. At 86.25, it suggests that investors are paying a significant premium for each rupee of earnings compared to the broader market, potentially indicating high growth expectations or overvaluation. To benchmark this, we observe its sector peers.
Mankind Pharma Ltd, for instance, enjoys significant market confidence partly attributed to its established brand and perceived management quality. While we are not directly comparing PE Ratios as they are not provided for these companies, the market sentiment surrounding management significantly influences valuations.The ROCE of 3.18% is a critical area of concern. ROCE indicates how efficiently a company generates profit from its capital employed. A low ROCE, such as Ganga Pharmaceuticals' current value, suggests that the company is not effectively utilizing its resources to generate returns. This impacts the company's economic moat – its ability to protect its profitability and market share from competitors. A higher ROCE typically signifies a stronger moat, allowing the company to reinvest profits and grow sustainably. A low ROCE may indicate difficulty in achieving sustainable competitive advantages.
In conclusion, while Ganga Pharmaceuticals share price reflects current market valuation, a thorough review of its financial performance and comparison with its competitors is crucial. The high PE ratio should be viewed in light of the comparatively low ROCE. Further investigation into the company's debt levels, cash flow, and growth prospects is necessary to understand the long-term sustainability of the business. This analysis is purely observational and does not constitute a recommendation to buy, sell, or hold Ganga Pharmaceuticals shares.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ganga Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GANGAPHARM across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (50.91%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
10 factors identified
Below-Average Return on Equity (1.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.18%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.00%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 86.25x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (-3.67% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-18.77% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-15.89% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (1.38x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-2.43 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ganga Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Ganga Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About GANGAPHARM (Ganga Pharmaceuticals Ltd)
Ganga Pharmaceuticals Ltd (GANGAPHARM) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹6.90 (Cr). Ganga Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 1.13% and a ROCE of 3.18%. The debt-to-equity ratio stands at 0.19, reflecting the company's capital structure. Investors tracking GANGAPHARM share price can monitor key metrics including P/E ratio, promoter holding of 50.91%, and quarterly earnings growth.
Company Details
Key Leadership
GANGAPHARM Share Price: Frequently Asked Questions
What is the current share price of Ganga Pharmaceuticals Ltd (GANGAPHARM)?
As of 13 Feb 2026, 10:05 am IST, Ganga Pharmaceuticals Ltd share price is ₹12.00. The GANGAPHARM stock has a market capitalisation of ₹6.90 (Cr) on NSE/BSE.
Is GANGAPHARM share price Overvalued or Undervalued?
GANGAPHARM share price is currently trading at a P/E ratio of 86.25x, compared to the industry average of 31.77x. Based on this relative valuation, the Ganga Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GANGAPHARM share price?
The 52-week high of GANGAPHARM share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Ganga Pharmaceuticals Ltd share price?
Key factors influencing GANGAPHARM share price include quarterly earnings growth (Sales Growth: 4.58%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ganga Pharmaceuticals Ltd a good stock for long-term investment?
Ganga Pharmaceuticals Ltd shows a 5-year Profit Growth of -15.89% and an ROE of 1.13%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.19 before investing in GANGAPHARM shares.
How does Ganga Pharmaceuticals Ltd compare with its industry peers?
Ganga Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare GANGAPHARM share price P/E of 86.25x and ROE of 1.13% against the industry averages to determine competitive standing.
What is the P/E ratio of GANGAPHARM and what does it mean?
GANGAPHARM share price has a P/E ratio of 86.25x compared to the industry average of 31.77x. Investors pay ₹86 for every ₹1 of annual earnings.
How is GANGAPHARM performing according to Bull Run's analysis?
GANGAPHARM has a Bull Run fundamental score of 13/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GANGAPHARM belong to?
GANGAPHARM operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ganga Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for GANGAPHARM?
GANGAPHARM has an ROE of 1.13%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Ganga Pharmaceuticals Ltd generates profits from shareholders capital.
How is GANGAPHARM debt-to-equity ratio and what does it indicate?
GANGAPHARM has a debt-to-equity ratio of 0.19, which indicates conservative financing with low financial risk.
What is GANGAPHARM dividend yield and is it a good dividend stock?
GANGAPHARM offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Ganga Pharmaceuticals Ltd shares.
How has GANGAPHARM share price grown over the past 5 years?
GANGAPHARM has achieved 5-year growth rates of: Sales Growth -3.67%, Profit Growth -15.89%, and EPS Growth -18.77%.
What is the promoter holding in GANGAPHARM and why does it matter?
Promoters hold 50.91% of GANGAPHARM shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Ganga Pharmaceuticals Ltd.
What is GANGAPHARM market capitalisation category?
GANGAPHARM has a market capitalisation of ₹7 crores, placing it in the Small-cap category.
How volatile is GANGAPHARM stock?
GANGAPHARM has a beta of N/A. A beta > 1 suggests the Ganga Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GANGAPHARM operating profit margin trend?
GANGAPHARM has a 5-year average Operating Profit Margin (OPM) of 0.00%, indicating the company's operational efficiency.
How is GANGAPHARM quarterly performance?
Recent quarterly performance shows Ganga Pharmaceuticals Ltd YoY Sales Growth of 4.58% and YoY Profit Growth of 0.00%.
What is the institutional holding pattern in GANGAPHARM?
GANGAPHARM has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Ganga Pharmaceuticals Ltd stock.